Stay updated on Pembrolizumab vs Placebo in Locally Advanced Cutaneous SCC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs Placebo in Locally Advanced Cutaneous SCC Clinical Trial page.

Latest updates to the Pembrolizumab vs Placebo in Locally Advanced Cutaneous SCC Clinical Trial page
- Check5 days agoChange DetectedThe webpage has been updated to include new results reporting dates and definitions related to recurrence-free survival (RFS) and overall survival (OS), along with changes in the assessment of quality of life for participants. Additionally, some previous reporting dates have been removed.SummaryDifference6%
- Check12 days agoChange DetectedThe web page has been updated from version 2.16.5 to version 2.16.6.SummaryDifference0.0%
- Check19 days agoChange DetectedA service alert has been added indicating planned maintenance starting July 25th, during which most services will be unavailable for over 24 hours.SummaryDifference0.5%
- Check27 days agoChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed. Notably, the information regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.SummaryDifference0.6%
- Check34 days agoNo Change Detected
- Check41 days agoChange DetectedThe modernization of the ClinicalTrials.gov data ingest has been postponed to July 2025, and the expected duration of the treatment has been extended from approximately 60 months to 62 months. Additionally, the registry identifiers have been updated.SummaryDifference3%
- Check48 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.0%
Stay in the know with updates to Pembrolizumab vs Placebo in Locally Advanced Cutaneous SCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Placebo in Locally Advanced Cutaneous SCC Clinical Trial page.